In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.
Set Alert for Articles By Akriti Seth

Latest From Akriti Seth

Civica Interested In Retired Or Withdrawn ANDAs

As a part of its strategy to develop its own ANDAs for essential medications, Civica has expressed interest in taking over existing ANDAs that are being retired or withdrawn by other generics manufacturers.

Strategy Generic Drugs

NBK Takes Control Of Morocco’s Polymedic

NBK Capital Partners has acquired a majority stake in Polymedic, which is based in Morocco, the sixth largest pharmaceutical market in Africa that is expected to reach $2bn in 2020.

Deals Morocco

Alvotech And JAMP Partner On Canadian Biosimilars

Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.

Deals Biosimilars

Mundipharma Partners With Samsung Bioepis For Hong Kong And Taiwan

Mundipharma and Samsung Bioepis are undertaking an exclusive commercialization partnership for a portfolio of biosimilars in Hong Kong and Taiwan.

Deals Biosimilars

Novo Nordisk Launches Low-Priced Insulin In US

Novo Nordisk says it is offering solutions to the unaffordability and inaccessibility of insulin by launching US authorized generics of its NovoLog and NovoLog Mix brands. The originator is also introducing a ‘My$99Insulin’ plan and an ‘immediate supply’ option to “help people with diabetes who need alternative solutions.”

United States Launches

AAM Urges Congress To Re-evaluate Blocking Act

Pointing out the “critical shortcomings of the Blocking Act” in a new report, the AAM has urged the US Congress to re-evaluate the legislation.

Legislation United States
See All
UsernamePublicRestriction

Register